Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Apogee Therapeutics Inc. (APGE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 566 | $1,934,022 | 0.72% | ||
| 2. | Bayforest Capital Theodoros Tsagaris | 6,063 | $510,323 | 0.57% | |
| 3. | 0 | $0 | 0% | ||
| 4. | Persistent Asset Partners Xin Huang | 0 | $0 | 0% | |
| 5. | Antipodes Partners Jacob Mitchell | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.85 | 12,500 | $623,125.00 | 20,000 | 2024-12-12 | Filing | |
| $49.02 | 7,500 | $367,650.00 | 7,500 | 2024-12-12 | Filing | |
| $17.00 | 1,750,000 | $29,750,000.00 | 1,750,000 | 2023-07-13 | Filing | |
| $17.00 | 892,529 | $15,172,993.00 | 892,529 | 2023-07-13 | Filing | |
| $17.00 | 1,992,734 | $33,876,478.00 | 1,992,734 | 2023-07-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $84.60 | 1,800 | $152,280.00 | 207,023 | 2026-05-06 | Filing | |
| $83.92 | 3,700 | $310,504.00 | 208,823 | 2026-05-06 | Filing | |
| $83.16 | 289 | $24,033.24 | 173,371 | 2026-05-01 | Filing | |
| $82.60 | 900 | $74,340.00 | 173,660 | 2026-05-01 | Filing | |
| $81.02 | 811 | $65,707.22 | 174,560 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,502,095 | $210,601,336 | 0.01% | |
| 2. | 1,144,328 | $96,318,088 | 0.01% | |
| 3. | 585,016 | $49,240,797 | 0.03% | |
| 4. | 442,738 | $37,265,257 | 0.06% | |
| 5. | 396,330 | $33,359,096 | 0% |
News See All
Wedbush Raises Price Target on Apogee Therapeutics (APGE)
On March 3, Wedbush increased its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) from $90 to $95.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Here is Why Apogee Therapeutics (APGE) Appears Attractive
Selloff in Apogee Therapeutics (APGE) stock, following the release of Sanofi’s Phase 3 amlitelimab data, is viewed as a market overreaction by Meacham.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best 52-week high stocks to buy right now. On December 3, TD Cowen’s Tyler Van Buren reiterated a Buy rating on Apogee Therapeutics Inc.
12 Best 52-Week High Stocks to Buy Right Now
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks.
BTIG Maintains a Buy on Apogee Therapeutics (APGE)
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best healthcare stocks with the highest upside. BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc.
Hedge Fund Resource Center